Veru Stock News

Veru''s (VERU) sabizabulin was granted the U.S. Food and Drug Administration''s fast track designation to treat hospitalized patients with COVID-19 who are at high risk for acute…

-- Phase 3 Sabizabulin COVID-19 Clinical Study for Treatment of Hospitalized Moderate to Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome Being Conducted in US, Mexico, So

The FDA has granted Fast Track designation to Veru Inc's VERU sabizabulin, oral cytoskeleton disruptor, to combat COVID-19 infection and the cytokine storm responsible for Acute Respiratory Distre

MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer,

MIAMI, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, to

The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

The FDA bestows a Fast Track designation to Veru's (VERU) phase III program evaluating enobosarm for treating AR+ER+HER2- metastatic breast cancer. Shares rise.

The company wins Fast Track designation for a top pipeline program.

The company wins Fast Track designation for a top pipeline program.

Gainers TSR, Inc. (NASDAQ: TSRI ) shares climbed 36.6% to $12.21 following Q2 results. The company reported Q2 revenue of $23.9 million, versus $16.1 million year over year. Accolade, Inc. (NASDAQ: ACCD ) gained 27.3% to $24.36 after the company reported Q3 earnings results and raised FY22 sales guidance. Nuverra Environmental Solutions, Inc. (NYSE: NES ) shares jumped 22.6% to $2.8450. BARK, Inc. (NYSE: BARK ) gained 18% to $4.25. The company said it expects Q3 sales of $140 million, versus analysts’ estimates of $137.3 million. BARK co-founder and executive chairman Matt Meeker will cecome CEO. Nutriband Inc. (NASDAQ: NTRB ) jumped 17.2% to $7.08. Nutriband and Kindeva Drug Delivery, on Monday, signed a feasibility agreement to develop AVERSA Fentanyl, an abuse deterrent fentanyl patch. Veru Inc. (NASDAQ: VERU ) surged 17% to $6.25. Veru, on Monday, said that its Enobosarm was granted fast track designation by the FDA. Cingulate Inc. (NASDAQ: CING ) jumped 15% to $2.82. Aegis Capital initiated coverage on Cingulate with a Buy rating and announced a price target of $9.

Veru <> shares have recovered after five straight sessions of losses on above-average volume as the market react to the Fast Track Designation granted by the FDA to the…

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ: VERU)'s Enobosarm was granted fast track designation for the treatment of AR+ ER+ HER2- metastatic breast cancer by the FDA

On CNBCs "Mad Money Lightning Round," Jim Cramer said Veru Inc. (NASDAQ: VERU )''s Enobosarm was granted fast track designation for the treatment of AR+ ER+ HER2- metastatic breast cancer by the FDA. With the companys stock trading at $5 and not moving higher, he said the stock should have been higher following the news. Cramer said he is not recommending NIO Inc. (NYSE: NIO ) or any of the Full story available on Benzinga.com

Veru (VERU) announces that the FDA has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm, for the treatment of AR+ER+HER2-

-- FDA Fast Track Designation is Intended to Expedite the Development and Review of New Drugs to Treat Serious Medical Conditions that Fill Unmet Medical Need -- -- Phase 3 ARTEST Registration Study of E nobosarm in Patients with AR+ ER+ HER2- Metastatic Breast Cancer Who Have Shown Previous Disease Progression on a Nonsteroidal AI, Fulvestrant, and a CDK 4/6 Inhibitor is Currently Enrolling -- MIAMI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU ), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm, a selective androgen receptor targeting agonist, for the treatment of androgen receptor positive, estrogen receptor positive, human epidermal growth factor receptor 2 negative (AR+ER+HER2-) metastatic breast cancer patients who have shown previous disease progression on a nonsteroidal AI, fulvestrant, and CDK 4/6 inhibitor therapy, and who have AR% nuclei staining 40% in breast cancer tissue (third-line metastatic setting). "We are very pleased that enobosarm has received Fast Track designation from the FDA, a distinction that underscores the urgent need for new, novel, targeted therapies for this important patient population suffering from this aggressive disease," said Mitchell Steiner, MD, Chairman, President and Chief Executive Officer of Veru Inc. "We look forward to ongoing, productive regulatory interactions with the FDA, which are further enabled with this designation." About Fast Track Designation Fast Track designation aims to expedite the development and review of new drugs that are intended to treat serious or life-threatening conditions and demonstrate the potential to fill unmet medical needs.